Saltar al contenido
Merck

Endogenous glutamine decrease is associated with pancreatic cancer progression.

Oncotarget (2017-12-10)
Cecilia Roux, Chiara Riganti, Sammy Ferri Borgogno, Roberta Curto, Claudia Curcio, Valeria Catanzaro, Giuseppe Digilio, Sergio Padovan, Maria Paola Puccinelli, Monica Isabello, Silvio Aime, Paola Cappello, Francesco Novelli
RESUMEN

Pancreatic ductal adenocarcinoma (PDAC) is becoming the second leading cause of cancer-related death in the Western world. The mortality is very high, which emphasizes the need to identify biomarkers for early detection. As glutamine metabolism alteration is a feature of PDAC, its

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Nα-Acetyl-L-glutamine